Breaking News

WuXi Biologics Makes Second Major Investment in Ireland

To build a $240 million vaccine manufacturing facility on its Dundalk site.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, said that its subsidiary WuXi Vaccines, engaged in human vaccine contract development and manufacturing organization (CDMO) business, is to invest $240 million and build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent (LOI) signed by WuXi Vaccines earlier this year.   U...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters